NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 80 taking part
- Started
- 20 Dec 2019
- Primary completion
- 13 Apr 2026
- Arms
- Nivolumab + Ipilimumab
- Results
- None posted
- 6 Sep 2019: Trial registered
- 20 Dec 2019: Trial started